Fixing the Subscription Trap
The FTC’s Negative Option Rule do-over – and what’s at stake.
Plowden et al. v. Similasan Corp.
23-cv-2511, D. Colo.
(Sept. 2023)
Similasan Eye Relief products
Marketing products as able to relieve various eye issues – including watery eyes, grittiness, redness, strain, and burning – when the company does not have FDA approval to make such drug claims and has not shown that the products are “generally recognized as safe and effective”
Settled
(Final approval granted)
https://www.homeopathiceyedropsettlement.com/home
The FTC’s Negative Option Rule do-over – and what’s at stake.
Be wary of questionable and deceptive claims in origin stories.
Mounting lawsuits accuse Meta of breaking privacy promises.
Breaking down the fine print of this March Madness commercial.
Advertised $19.99 price deserves an official review.